Poxel SA POXEL

LYON, France, September 03, 2026--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company that has developed innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases, announces the appointment of Laure-Hélène Mercier as Chair of the Board of Directors, effective September 3, 2026, to replace Sophie Jacq Lapointe.

LYON, France, July 30, 2026--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company that has developed innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases, today publishes its revenue figures for the second quarter ended 30 June 2026.

LYON, France, June 10, 2026--Regulatory News: Poxel (Euronext: POXEL - FR0012432516), a biopharmaceutical company listed on Euronext Paris, announces the appointment of Yves Decadt as Chief Executive Officer with effect from 10 June 2026. He succeeds Nicolas Trouche, whose role was specifically designed to support Poxel during the restructuring period that began in August 2025, with the aim of successfully developing and implementing the Continuation Plan. This transition, previously agreed to t

SCYNEXIS (SCYX) said Tuesday that it has entered into a securities purchase agreement with investors

PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progressionA Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027With this acquisition, SCYNEXIS strengthens its mission to develop innovative solutions for severe and rare diseases, unlocking further opportunities for value